VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET ANALYSIS
Global Viral Vector and Plasmid DNA Testing Services Market- Key Developments
In January 2022, Sarepta Therapeutics, Inc., a biotechnology company, and Aldevron, A corporate company, collaborated for the supply of GMP grade plasmid to meet the needs of Sarepta's gene therapy clinical trials and commercial supply.
In August 26, 2021, INOVIO, a biotechnology has announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine).
In July 2021, Thermo Fisher Scientific, a pharmaceutical company, announced the opening of its new cGMP (Current good manufacturing practices) plasmid DNA manufacturing facility in Carlsbad California, U.S.
In June, 2020, Genprex, Inc., a clinical-stage gene therapy company, announced collaboration with Aldevron, a biotechnology company, in order to manufacture GMP plasmid DNA for Genprex's Oncoprex gene therapy portfolio.
Viral Vector And Plasmid Dna Testing Services Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request DiscountPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :